The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 30, 2019

Filed:

Oct. 27, 2014
Applicant:

Oxthera Intellectual Property Ab, Stockholm, SE;

Inventors:

Qingshan Li, Gainesville, FL (US);

Harmeet Sidhu, Gainesville, FL (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 9/51 (2006.01); A61K 38/44 (2006.01); A61K 38/45 (2006.01); A61K 38/48 (2006.01); A61K 38/51 (2006.01); A61K 47/36 (2006.01);
U.S. Cl.
CPC ...
A61K 9/1652 (2013.01); A61K 9/5036 (2013.01); A61K 9/5073 (2013.01); A61K 9/5089 (2013.01); A61K 9/5161 (2013.01); A61K 9/5192 (2013.01); A61K 38/44 (2013.01); A61K 38/45 (2013.01); A61K 38/488 (2013.01); A61K 38/51 (2013.01); A61K 47/36 (2013.01); C12Y 102/03004 (2013.01); C12Y 208/03016 (2013.01); C12Y 304/23002 (2013.01); C12Y 401/01002 (2013.01); C12Y 401/01008 (2013.01); A61K 9/5115 (2013.01);
Abstract

The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.


Find Patent Forward Citations

Loading…